---
title: "Barclays Sticks to Their Buy Rating for Collegium Pharmaceutical (COLL)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296320846.md"
description: "Barclays analyst Jenna Davidner reiterated a Buy rating on Collegium Pharmaceutical (COLL) with a $48 price target, noting the stock closed at $28.50. The broader analyst consensus remains a Strong Buy with an average target of $49.25, implying significant upside. Additionally, H.C. Wainwright reaffirmed its Buy rating on August 7 with a higher $60 target."
datetime: "2026-08-19T07:27:44.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296320846.md)
  - [en](https://longbridge.com/en/news/296320846.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296320846.md)
generator: "portal-rs"
---

# Barclays Sticks to Their Buy Rating for Collegium Pharmaceutical (COLL)

Barclays analyst Jenna Davidner reiterated a Buy rating on Collegium Pharmaceutical yesterday and set a price target of $48.00. The company’s shares closed yesterday at $28.50.

### Summer Sale - Claim 70% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

According to TipRanks, Davidner is an analyst with an average return of -2.6% and a 41.18% success rate. Davidner covers the Healthcare sector, focusing on stocks such as Collegium Pharmaceutical, Pacira Pharmaceuticals, and Phathom Pharmaceuticals.

Currently, the analyst consensus on Collegium Pharmaceutical is a Strong Buy with an average price target of $49.25, which is a 72.81% upside from current levels. In a report released on August 7, H.C. Wainwright also reiterated a Buy rating on the stock with a $60.00 price target.

### Related Stocks

- [COLL.US](https://longbridge.com/en/quote/COLL.US.md)
- [BCS.US](https://longbridge.com/en/quote/BCS.US.md)
- [PCRX.US](https://longbridge.com/en/quote/PCRX.US.md)
- [PHAT.US](https://longbridge.com/en/quote/PHAT.US.md)
- [BARC.UK](https://longbridge.com/en/quote/BARC.UK.md)

## Related News & Research

- [Collegium Pharma management joins Morgan Stanley Global Healthcare Conference fireside chat](https://longbridge.com/en/news/298315836.md)
- [Collegium Pharmaceutical (COLL) Reports Earnings Tomorrow: What To Expect](https://longbridge.com/en/news/294905631.md)
- [4,000 Shares in Ligand Pharmaceuticals Incorporated $LGND Acquired by JW Asset Management LLC](https://longbridge.com/en/news/298374596.md)
- [Is Collegium Pharmaceutical (COLL) A Bargain On Its Azstarys Deal And 2026 Guidance?](https://longbridge.com/en/news/291686028.md)
- [Analyst Brandon Vazquez Reaffirms Buy on Medtronic, Citing Strong FY2027 Outlook and Attractive Risk‑Reward Profile](https://longbridge.com/en/news/298641077.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**